Applied DNA Sciences, Inc.
NASDAQ Capital MarketTotal Valuation
Applied DNA Sciences, Inc. carries a market capitalization of 7.26M, placing it among publicly traded companies globally. Its enterprise value stands at -3.41M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 7.26M |
| Enterprise Value | -3.41M |
Share Statistics
Applied DNA Sciences, Inc. currently has 901,500.00 shares outstanding.
| Shares Outstanding | 901,500.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.38, and the price-to-book ratio stands at 0.00.
| PE Ratio | N/A |
| PS Ratio | 0.38 |
| PB Ratio | 0.00 |
| P/TBV Ratio | 0.29 |
| P/FCF Ratio | -0.11 |
| P/OCF Ratio | -0.10 |
Enterprise Valuation
| EV / Sales | 83.65 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Applied DNA Sciences, Inc. maintains a current ratio of 2.76, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.76 |
| Quick Ratio | 2.42 |
| Debt / Equity | 4.79 |
| Debt / EBITDA | -0.03 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -99.05 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 4.93 |
Stock Price Statistics
Applied DNA Sciences, Inc.'s stock has declined approximately -95.97997% over the past 52 weeks. The 50-day moving average sits at 3.55, while the 200-day moving average is 35.61.
| Beta (5Y) | N/A |
| 52-Week Price Change | -95.97997% |
| 50-Day Moving Average | 3.55 |
| 200-Day Moving Average | 35.61 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Applied DNA Sciences, Inc. generated 3.30M in revenue and converted that into -13.19M in net income, yielding earnings per share of -53.12. EBITDA reached -13.06M, while operating income came in at -13.39M.
| Revenue | 3.30M |
| Gross Profit | 1.30M |
| Operating Income | -13.39M |
| Pretax Income | -12.97M |
| Net Income | -13.19M |
| EBITDA | -13.06M |
| EBIT | -13.39M |
| Earnings Per Share (EPS) | -53.12 |
Balance Sheet
Applied DNA Sciences, Inc. holds 4.73M in cash and equivalents against 334,403.00 in total debt, resulting in a net debt position of -4.73M. Total book value stands at -373.89M, with working capital of 3.59M providing operational flexibility.
| Cash & Cash Equivalents | 4.73M |
| Total Debt | 334,403.00 |
| Net Debt | -4.73M |
| Equity (Book Value) | -373.89M |
| Book Value Per Share | -1,531.81 |
| Working Capital | 3.59M |
Cash Flow
Applied DNA Sciences, Inc. produced -12.58M in operating cash flow over the past twelve months. After subtracting -684,371.00 in capital expenditures, free cash flow totaled -13.26M - equivalent to -54.33 per share.
| Operating Cash Flow | -12.58M |
| Capital Expenditures | -684,371.00 |
| Free Cash Flow | -13.26M |
| FCF Per Share | -54.33 |
Margins
Applied DNA Sciences, Inc. operates with a gross margin of 39.58, reflecting its pricing power and cost economics. The operating margin of -406.10 and net profit margin of -399.87 provide insight into operational efficiency.
| Gross Margin | 39.58 |
| Operating Margin | -406.10 |
| Pretax Margin | -393.22 |
| Profit Margin | -399.87 |
| EBITDA Margin | -396.01 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -599.65 |
| FCF Yield | -946.05 |
Stock Splits
Applied DNA Sciences, Inc.'s most recent stock split took place on June 2, 2025 with a 15:1 split ratio.
| Last Split Date | 6/2/2025 |
| Split Ratio | 15:1 |
Scores
Applied DNA Sciences, Inc. posts an Altman Z-Score of -77.14, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -77.14 |